Despite the fact that Temsirolimus is not indicated in the second line of therapy in metastatic clear cell carcinoma according to the guidelines but also to the results of the phase II study mentioned before, this mTOR inhibitor was used after Sunitinib in a patient with metastatic clear renal cell carcinoma. This evidence concerns the gene MTOR and clear cell renal carcinoma.